Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

glofitamab-gxbm

View Patient Information
A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab-gxbm binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.
Synonym:anti-CD20 x anti-CD3 bispecific monoclonal antibody RO7082859
anti-CD20/CD3 bispecific monoclonal antibody RO7082859
glofitamab
US brand name:Columvi
Code name:RO 7082859
RO7082859
Search NCI's Drug Dictionary